WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2008103046) A CONTROLLED RELEASE COMPOSITION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2008/103046    International Application No.:    PCT/NL2008/050106
Publication Date: 28.08.2008 International Filing Date: 21.02.2008
IPC:
A61K 9/00 (2006.01), A61K 9/06 (2006.01), A61K 47/42 (2006.01)
Applicants: FUJIFILM Manufacturing Europe B.V. [NL/NL]; Oudenstaart 1, NL-5047 TK Tilburg (NL) (For All Designated States Except US).
KLUIJTMANS, Sebastianus Gerardus Johannes Maria [NL/NL]; (NL) (For US Only).
SUTTER, Marc [CH/NL]; (NL) (For US Only).
JISKOOT, Wim [NL/NL]; (NL) (For US Only).
HENNINK, Wilhelmus Everhardus [NL/NL]; (NL) (For US Only).
BOUWSTRA, Jan Bastiaan [NL/NL]; (NL) (For US Only)
Inventors: KLUIJTMANS, Sebastianus Gerardus Johannes Maria; (NL).
SUTTER, Marc; (NL).
JISKOOT, Wim; (NL).
HENNINK, Wilhelmus Everhardus; (NL).
BOUWSTRA, Jan Bastiaan; (NL)
Priority Data:
07102838.5 21.02.2007 EP
Title (EN) A CONTROLLED RELEASE COMPOSITION
(FR) COMPOSITION À LIBÉRATION CONTRÔLÉE
Abstract: front page image
(EN)The invention relates to the field of pharmacology. More specific, the invention relates to a controlled release composition. This invention is related to a controlled release composition comprising a cross-linked gelatin and at least one therapeutic protein wherein the ratio of the average mesh size (ξ) of the gelatin matrix and the average hydrodynamic radius (RH) of the therapeutic protein is smaller than 2, preferably smaller than 1.5.
(FR)L'invention concerne le domaine de la pharmacologie. Plus spécifiquement, l'invention porte sur une composition à libération contrôlée. Cette invention porte sur une composition à libération contrôlée comprenant une gélatine réticulée et au moins une protéine thérapeutique, le rapport de la dimension de maille moyenne (ξ) de la matrice de gélatine et du rayon hydrodynamique moyen (RH) de la protéine thérapeutique étant inférieur à 2, de préférence inférieur à 1,5.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)